HomeNewsBusinessAmul expects 18% growth in turnover to around Rs 46,000 crore this fiscal

Amul expects 18% growth in turnover to around Rs 46,000 crore this fiscal

In an interview with PTI, Amul MD RS Sodhi said: "We are expecting around 18 percent growth this fiscal year to about Rs 46,000 crore." The demand for all products, like butter, ice cream, milk, has improved, he added

March 06, 2022 / 11:56 IST
Story continues below Advertisement
Representative image: Reuters
Representative image: Reuters

Gujarat Cooperative Milk Marketing Federation (GCMMF), which markets dairy products under the Amul brand, is expecting an 18 percent growth in its turnover this fiscal year to around Rs 46,000 crore on better demand, Managing Director RS Sodhi said.

India's leading dairy cooperative, GCMMF had posted a marginal growth of 2 percent during FY21 to Rs 39,200 crore despite the COVID-19 pandemic.

Story continues below Advertisement

In an interview with PTI, Sodhi said: "We are expecting around 18 percent growth this fiscal year to about Rs 46,000 crore." The demand for all products, like butter, ice cream, milk, has improved, he added.

In volume terms also, Sodhi said the growth will be around 15 percent. In the last financial year, the GCMMF turnover grew marginally as sales of ice cream were down 35 percent mainly because of the nationwide lockdown during the summer to curb the COVID-19 pandemic. The commodity business of products like skimmed milk powder (SMP) was also impacted.

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show